Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 26, 2026

Has The Recent Rally Left Dell Technologies (DELL) Fully Priced Or Still Attractive?

View original at finance.yahoo.com
“For Dell Technologies, the model uses last twelve months Free Cash Flow of about $8.1b”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dell Technologies shares trade at an 18.3% discount to intrinsic value, indicating the stock appears undervalued on a DCF basis

    60% confidence

  • Dell Technologies has a valuation score of 3 out of 6, based on how often it screens as undervalued across several checks

    60% confidence

  • Sentiment shifts driven by headlines around key technology trends and investor interest in large established tech names can push prices away from what underlying cash flows and fundamentals suggest

    60% confidence

  • Dell Technologies DCF intrinsic value is approximately $264.59 per share based on the 2 Stage Free Cash Flow to Equity model using TTM FCF of $8.1 billion

    60% confidence

  • Dell Technologies projected Free Cash Flow is $11.7 billion in 2031 based on analyst inputs and Simply Wall St extrapolation

    60% confidence

Data points we hold from this source

Dell Technologies · cash8.1 USD
Dell Technologies · margin-18.3 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Has The Recent Rally Left Dell Technologies (DELL) Fully Priced Or Still Attractive? — Source | Via News | ViaNews EU